Australian Clinical Labs Limited (ASX:ACL) Directors Insider Transactions
The Directors and Chief Executives of Australian Clinical Labs Limited (ASX:ACL) are required by law to report any insider transaction activities i.e. buying, selling, option exercising the Australian Clinical Labs Limited's shares in the stock market. Below table shows the list of insider transactions as reported by Australian Clinical Labs Limited to the ASX stock exchange.
An insider trade occurs when an individual (such as a CEO, CFO or COO) that has non-public information about a company buys or sells shares of that company's stock. Tracking a company's insider trades is a metric that can be used to identify the direction that the company's executives believes that the company is headed. For example, if a number of insiders purchase more shares of a company, they may believe that the company will have strong future earnings and that the share price will increase in the near future.
Australian Clinical Labs Limited Directors/Insider Transactions Activity
List of Insider trades activity from Australian Clinical Labs Limited (ACL).
| Date | Director | Director's Title | Shares | Value | Note |
|---|---|---|---|---|---|
| 19 Feb 2026 | Butler (Sarah) | Director (Non-Executive) | 22,617 | 35,277 | Purchase at price 1.56 per share. |
| 28 Oct 2025 | Roche (Stephen) | Director (Non-Executive) | 70,000 | 127,624 | Purchase at price 1.82 per share. |
| 22 Oct 2025 | Rowe (Leanne) | Former | 5,000 | - | - |
| 30 Apr 2025 | Alscher (Michael Thomas) | Former | 280,502 | - | - |
| 25 Oct 2024 | Dutton (Andrew Mark Rendle CPA) | Former | 81,897 | - | - |